Inhibikase Therapeutics, Inc.
IKT•NASDAQ•Healthcare•Biotechnology

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMark Iwicki
Founded2008
IPO DateDecember 23, 2020
Employees16
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.inhibikase.com
Phone678 392 3419
Address
3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 United States

Corporate Identifiers

CIK0001750149
CUSIP45719W106
ISINUS45719W2052
EIN26-3407249
SIC2836

Leadership Team & Key Executives

Mark T. Iwicki
Chief Executive Officer and Director
Dr. Christopher H. Cabell FACC, M.D.
President, Head of Research and Development and Chief Medical Officer
David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A.
Chief Financial Officer
Dr. John Adams Ph.D.
Chief Scientific Officer
Jeffrey J. Kagy
Chief Human Resources Officer
Chadwick J. Orevillo MPH
Executive Vice President and Head of Development Operations
Timothy J. Pigot
Chief Commercial and Strategy Officer